Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

The Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) funding opportunity is administered by the National Institutes of Health within the U.S. Department of Health and Human Services. NIH is the primary federal agency responsible for biomedical and public health research in the United States, supporting a wide range of initiatives to improve health outcomes and advance scientific knowledge. This particular opportunity aligns with NIH’s mission by focusing on advancing precision medicine and therapeutic safety for vulnerable populations including pregnant women, lactating women, fetuses, neonates, and children. The purpose of this funding opportunity is to support translational and clinical research that bridges basic scientific discoveries with real-world clinical applications. Specifically, it aims to advance precision medicine approaches through the development of innovative tools, models, and technologies that can directly impact patient care. The program emphasizes improving understanding of drug action mechanisms, including how physiological changes during pregnancy and childhood development affect pharmacology. It also supports efforts to discover new therapeutics or improve the safety and efficacy of existing medications, including drug repurposing strategies. Funding under this opportunity is provided through the R01 grant mechanism, which typically supports discrete, specified, and circumscribed research projects. While specific funding amounts are not provided in the summary, R01 grants generally support multi-year research projects with flexible use of funds for personnel, equipment, supplies, and other allowable research-related expenses. There is no cost-sharing or matching requirement, which lowers the financial barrier for applicants and aligns with NIH’s standard funding structure. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of applicant types. Eligible entities include federal, state, and local government agencies; public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations including small businesses; tribal governments and tribal organizations; school districts; and public housing authorities. Additional eligible applicants include minority-serving institutions such as Historically Black Colleges and Universities, Hispanic-serving institutions, and other designated groups, as well as foreign organizations and regional entities. This wide eligibility scope reflects NIH’s commitment to fostering diverse participation in research. The application process requires submission through standard NIH and Grants.gov mechanisms. Applicants must prepare a full research proposal that includes detailed scientific aims, methodology, budget justification, and supporting documentation as required under the R01 mechanism. Clinical trials are optional under this funding opportunity, allowing flexibility depending on the nature of the proposed research. Applicants are encouraged to consult the full announcement for detailed submission instructions and requirements, including formatting and review criteria. Applications are evaluated based on NIH’s established peer review process, which considers scientific merit, innovation, investigator qualifications, and potential impact. The opportunity was initially posted on November 18, 2024, with a current application deadline of July 7, 2026. While the opportunity includes a prior deadline, the updated closing date indicates an active submission window. Applicants can direct inquiries to NIH Grants Information via email at grantsinfo@nih.gov. The opportunity may be part of a recurring NIH funding cycle, although recurrence is not explicitly stated in the summary.